Jeremy Reimann, None;
James Murphy, None;
Chad Kaplan, None;
C Gustavo De Moraes, National Eye Institute (F), Research to Prevent Blindness (F);
Alon Skaat, None;
Lama Al-Aswad, None;
Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EySight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F);
Felipe Medeiros, Alcon (C), Allergan (F), Allergan (C), Ametek (F), Ametek (C), Bausch+Lomb (F), Carl Zeiss Meditec (F), Carl Zeiss Meditec (C), Carl Zeiss Meditec (R), Heidelberg Engineering (F), Heidelberg Engineering (C), Sensimed (F), Topcon (F);
Robert Weinreb, Alcon (C), Allergan (C), Amatek (C), Bausch+Lomb (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Carl Zeiss Meditech (C), Forsight (C), Genentech (F), Heidelberg Engineering (F), Konan (F), National Eye Institute (F), Neurovision (F), Optovue (F), Quark (F), Reichert (F), Tomey (F), Topcon (C), Topcon (F), Valeant (C);
Linda Zangwill, Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Heidelberg Engineering, GmbH (F), Optovue Inc (F), Optovue Inc (R), Quark (F), Topcon Medical Systems Inc. (F);
Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Bausch+Lomb (C), Bausch+Lomb (F), Carl Zeiss Meditech, Inc. (C), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (E), Diopysis, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc. (C), National Eye Institute (F), New York Glaucoma Research Institute (F), Optovue, Inc. (F), Quark Pharmaceuticals, Inc. (C), Reichert, Inc. (C), Reichert, Inc. (F), Sensimed, Inc. (C), SOLX, Inc. (F), SOLX, Inc. (E), Sustained Nano System (E), Sustained Nano System (P), Topcon, Inc. (F), Valeant Pharmaceuticals, Inc. (C)